What Is Happening With Innate Pharma Stock On Friday?

102
3
Favorite

What Is Happening With Innate Pharma Stock On Friday?

Benzinga2021-09-18

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

102

Report

Comment（3）

Troytan
·2021-09-19
Good news for Innate Pharma investors
Reply
4
Report
JayChou学投资
·2021-09-18
.
Reply
5
Report
Rickyt089
·2021-09-18
Like pls
Reply
3
Report
Fold Replies
- SSVC:
  [Strong][ShakeHands]
  2021-09-20
  Reply
  Report
- Geoz88:
  OK
  2021-09-19
  Reply
  Report
- SSVC:
  Ok
  2021-09-19
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2168575701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-18 06:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2168575701","market":"us","top_or_hot":-1,"title":"What Is Happening With Innate Pharma Stock On Friday?","media":"Benzinga","content":"<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPHA","symbol_name":"Innate Pharma SA","start_time":0,"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","article_id":"2168575701","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","pubTimestamp":1631916641,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"translate_title":"周五先天制药的股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"IPHA":0.9},"content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":887342831,"gmtCreate":1631984502723,"gmtModify":1676530682261,"author":{"id":"3571482048865852","authorId":"3571482048865852","name":"Troytan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3571482048865852","authorIdStr":"3571482048865852"},"htmlText":"Good news for Innate Pharma investors","listText":"Good news for Innate Pharma investors","text":"Good news for Innate Pharma investors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887342831","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","kind":"news","pubTimestamp":1631916641,"share":"https://ttm.financial/m/news/2168575701?lang=&edition=fundamental","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":887918126,"gmtCreate":1631956843765,"gmtModify":1676530678139,"author":{"id":"4091284646222870","authorId":"4091284646222870","name":"JayChou学投资","avatar":"https://static.tigerbbs.com/5bd8491c971437a5db7fb0829fdee4c4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4091284646222870","authorIdStr":"4091284646222870"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887918126","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","kind":"news","pubTimestamp":1631916641,"share":"https://ttm.financial/m/news/2168575701?lang=&edition=fundamental","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":884751294,"gmtCreate":1631936521218,"gmtModify":1676530674041,"author":{"id":"3571612770300673","authorId":"3571612770300673","name":"Rickyt089","avatar":"https://static.tigerbbs.com/4e75fb09fa53aa8d7db329d6599d40c1","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3571612770300673","authorIdStr":"3571612770300673"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/884751294","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","kind":"news","pubTimestamp":1631916641,"share":"https://ttm.financial/m/news/2168575701?lang=&edition=fundamental","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5927560,"gmtCreate":1632097519550,"gmtModify":1663234128353,"authorId":3574906731000207,"author":{"id":3574906731000207,"idStr":"3574906731000207","authorId":3574906731000207,"name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":5918379,"prevId":0,"content":"[Strong][ShakeHands]","text":"[Strong][ShakeHands]","html":"[Strong][ShakeHands]"},{"id":5919169,"gmtCreate":1632017597516,"gmtModify":1663234094527,"authorId":3579002978614578,"author":{"id":3579002978614578,"idStr":"3579002978614578","authorId":3579002978614578,"name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":5918379,"prevId":0,"content":"OK","text":"OK","html":"OK"},{"id":5918379,"gmtCreate":1632014127768,"gmtModify":1663234092943,"authorId":3574906731000207,"author":{"id":3574906731000207,"idStr":"3574906731000207","authorId":3574906731000207,"name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":102,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}